Evidence map›Paper›PMID 41131335›Full record

ReviewExperimental & molecular medicine2025

Redox regulation by sulfiredoxin-1: bridging cysteine oxidation and liver disease therapeutics.

Jong-Won Kim, Mengyun Ke, Donovan Whitfield, Bin Yang, Gu Seob Roh, Wen Xie

Abstract readReview
In one paragraph

Review in Experimental & molecular medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Jong-Won Kim *Center for Pharmacogenetics and Department of Pharmaceutical Sciences, University of Pittsburgh, Pittsburgh, PA, USA. kimjw@gnu.ac.kr.ORCID http://orcid.org/0009-0008-1219-6967
Mengyun Ke *Center for Pharmacogenetics and Department of Pharmaceutical Sciences, University of Pittsburgh, Pittsburgh, PA, USA.
Donovan WhitfieldCenter for Pharmacogenetics and Department of Pharmaceutical Sciences, University of Pittsburgh, Pittsburgh, PA, USA.ORCID http://orcid.org/0009-0006-7810-3482
Bin YangCenter for Pharmacogenetics and Department of Pharmaceutical Sciences, University of Pittsburgh, Pittsburgh, PA, USA.
Gu Seob RohDepartment of Anatomy, College of Medicine, Institute of Medical Science, Gyeongsang National University, Jinju, Republic of Korea.ORCID http://orcid.org/0000-0003-4010-9628
Wen XieCenter for Pharmacogenetics and Department of Pharmaceutical Sciences, University of Pittsburgh, Pittsburgh, PA, USA. wex6@pitt.edu.ORCID http://orcid.org/0000-0003-3967-155X

Funding

National Research Foundation of Korea (NRF) RS-2023-00219399National Research Foundation of Korea (NRF) RS-2025-00556031
6 · The paper itself

Abstract

Cysteine (Cys) posttranslational modifications play a critical role in regulating protein function, cellular signaling and redox homeostasis in various physiological and pathological conditions. Sulfiredoxin-1 (SRXN1) has emerged as a key regulator of protein redox homeostasis through its involvement in Cys sulfinylation. However, the role of SRXN1 in the pathogenesis of diseases and its therapeutic implications have yet to be fully explored. Beyond its classical function in reactive oxygen species detoxification, SRXN1 also modulates redox-sensitive signaling pathways that govern inflammation, apoptosis and cell survival, making it an essential component of cellular defense against oxidative stress-related damage. Here we highlight the significance of SRXN1 in regulating Cys sulfinylation across a broad spectrum of liver diseases. Furthermore, we emphasize the critical role of SRXN1 in regulating oxidative stress and cellular signaling through its interaction and desulfinylation of target or substrate proteins, both of which are crucial to maintaining cellular function under pathological conditions. Finally, we discuss the potential therapeutic implications of targeting SRXN1 in disease contexts where oxidative stress exacerbates pathological processes. A deeper understanding of SRXN1-mediated redox regulation may offer a novel therapeutic avenue to mitigate Cys oxidation and improve clinical outcomes in various liver disease contexts.

Indexed as

CysteineLiver DiseasesOxidoreductases Acting on Sulfur Group DonorsAnimalsHumansOxidation-ReductionOxidative StressProtein Processing, Post-TranslationalReactive Oxygen SpeciesSignal TransductionCysteineOxidoreductases Acting on Sulfur Group DonorsReactive Oxygen SpeciesSRXN1 protein, human

Identifiers

PMID41131335
PMCPMC12586646

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.